brinzolamide
Trade name: azopt
Approved
Apr 1, 1998
Brinzolamide reduces the amount of fluid in the eye, which decreases pressure inside the eye. Brinzolamide is a carbonic anhydrase inhibitor that is FDA approved for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Common adverse reactions include abnormal taste in mouth and blurred vision. The concomitant administration of brinzolamide and oral carbonic anhydrase inhibitors is not recommended. Plus, in patients treated with oral carbonic anhydrase inhibitors, rare instances of acid-base alterations have occurred with high-dose salicylate therapy. — NCATS
Clinical trial activity
68 trials · 34 clinical orgs · 10 marketing orgs
Earliest trial started Jan 1, 2003 (NCT00061516)
Timeline
1990s
2000s
2010s
- Apr 19, 2013
Alcon — NDA Secondary Org
- Apr 19, 2013
Nestle — NDA Secondary Org
- Jan 1, 2018
Bausch Health Companies — Earliest Phase 1 Sponsor(trial)
2020s
- Nov 27, 2020
Watson Pharmaceuticals — Marketing Organization
- Nov 27, 2020
AbbVie — Marketing Organization
- Aug 18, 2021
Bausch & Lomb — Marketing Organization
- Aug 18, 2021
Bausch Health Companies — Marketing Organization
- Jul 28, 2023
Padagis Us — Marketing Organization
- Nov 29, 2023
Perrigo — Marketing Organization
Indications
Approved for
Mechanism of action
- Carbonic anhydrase IIINHIBITOR
CA2 inhibitor
Combination products
simbrinza
with brimonidine
Also known as simbrinza 0.2%/1% ophthalmic suspension
Approval history
- approvedApr 1, 1998
Chemistry & pharmacology
SMILES
CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O- Mol. weight
- 383.507 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaBrinzolamide ↗
- NCATS9451Z89515 ↗
- ChEMBLCHEMBL220491 ↗
Also known as
- al-4862
- al-4862
- al-4862
- al-4862
- al-4862
- alcon brand of brinzolamide
- allphar brand of brinzolamide
- azopt
- azopt
- azopt
- azopt
- azopt
- azopt
- brinzolamide
- brinzolamide
- brinzolamide
- brinzolamide
- brinzolamide
- brinzolamide
- brinzolamide
- brinzolamide
- brinzolamide
- brinzolamide
- brinzolamide
- brinzolamide / brimonidine tartrate
- brinzolamide / timolol maleate
- elazop
- elazop
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06883123 | Phase 4 | May 14, 2025 | Prairie Eye Center, Sengi |
| NCT05022004 | Phase 3 | Dec 31, 2021 | Sun Pharmaceuticals |
| NCT04944290 | Phase 3 | May 28, 2021 | Perrigo |
| NCT04523844 | N/A | May 11, 2020 | General Hospital of Athens Elpis |
| NCT04296916 | N/A | Apr 30, 2020 | Sun Yat-Sen University |
| NCT04024072 | Phase 3 | Jun 24, 2019 | Perrigo |
| NCT03542006 | Phase 2 | Jun 1, 2018 | Tel Aviv University |
| NCT03896633 | Phase 1/Phase 2 (Phase 2) | Feb 26, 2018 | Bausch Health Companies |
| NCT03494257 | N/A | Sep 4, 2017 | University of Patras |
| NCT03150160 | Phase 4 | Aug 31, 2017 | Novartis |
| NCT03192826 | Phase 4 | Jun 20, 2016 | University of Patras |
| NCT02730871 | Phase 4 | Jun 17, 2016 | Alcon |
| NCT02770248 | Phase 4 | May 1, 2016 | Alcon |
| NCT02419508 | Phase 4 | Aug 7, 2015 | Alcon |
| NCT02512042 | Phase 3 | Apr 1, 2015 | Actavis |
| NCT02339584 | Phase 3 | Apr 1, 2015 | Alcon |
| NCT02325518 | Phase 4 | Dec 1, 2014 | Alcon, Novartis |
| NCT02390284 | Phase 3 | Sep 1, 2014 | National Eye Institute (NEI), University of Miami |
| NCT02167035 | Phase 4 | Aug 1, 2014 | Allergan, Cornerstone Health Care, PA |
| NCT02140060 | Phase 2 | Jun 1, 2014 | Alcon |
Organizations
Research & Development (34)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alcon | For profit | 43 | 40 | 4 | 2003 |
| Allergan | For profit | 2 | 1 | 1 | 2006 |
| Novartis | For profit | 2 | 2 | 1 | 2014 |
| Perrigo | For profit | 2 | 2 | 1 | 2019 |
| Singapore National Eye Centre | Academic/Hospital | 2 | 1 | 1 | 2007 |
| University of Patras | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Actavis | For profit | 1 | 1 | 1 | 2015 |
| Adapt Produtos Oftalmológicos Ltda. | For profit | 1 | 1 | 1 | 2012 |
| Afyon Kocatepe University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Aristotle University of Thessaloniki | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Bausch Health Companies | For profit | 1 | 1 | 1 | 2018 |
| Canadian Glaucoma Clinical Research Council | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Cornerstone Health Care, PA | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Credit Valley EyeCare | Academic/Hospital | 1 | 1 | 1 | 2012 |
| General Hospital of Athens Elpis | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Hermann Eye Center | Academic/Hospital | 1 | 1 | 1 | 2003 |
| InnoPharma | For profit | 1 | 1 | 1 | 2012 |
| National Eye Institute (NEI) | Government | 1 | 0 | 1 | 2014 |
| National University of Singapore | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Northeast Ohio Medical University | Academic/Hospital | 1 | 1 | 1 | 2011 |
Marketing (12)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | MKTG | Nov 27, 2020 |
| Alcon | For profit | NDA | Apr 1, 1998 |
| Alcon | For profit | NDA2 | Apr 19, 2013 |
| Bausch & Lomb | For profit | MKTG | Aug 18, 2021 |
| Bausch Health Companies | For profit | MKTG | Aug 18, 2021 |
| Nestle | For profit | NDA2 | Apr 19, 2013 |
| Novartis | For profit | NDA2 | Apr 1, 1998 |
| Novartis | For profit | SYN | Apr 1, 1998 |
| Padagis Us | For profit | MKTG | Jul 28, 2023 |
| Perrigo | For profit | MKTG | Nov 29, 2023 |
| Sandoz | For profit | MKTG | Apr 1, 1998 |
| Watson Pharmaceuticals | For profit | MKTG | Nov 27, 2020 |